| [1] Van Giezen J J, Humphries R G.Preclinical and clinical studies with selective reversible direct P2Y12 antagonists [J]. Semin Thromb Haemost, 2005, 31(2): 195-204.[2] Springthorpe B, Bailey A, Barton P, et al.From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis [J]. Bioorg Med Chem Lett, 2007, 17(21): 6013-6018.[3] Levine G N, Bates E R, Blankenship J C, et al.2011 ACCF /AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions [J]. Circulation, 2011, 124(23): 2574-2609.[4] Steg G, James S K, Atar D, et al.ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation [J]. Eur Heart J, 2012, 33(20): 2569-2619.[5] Pena A, Collet P, Hulot S, et al. Can we override clopidogrel resistance [J]. Circulation, 2009, 119(21): 2854-2857.[6] Gurbel P A, Bliden K P, Hayes K M, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post treatment platelet aggregation in patients undergoing coronary stenting [J]. J Am Coll Cardiol, 2005, 45(9): 1392-1396.[7] Storey R F, Bliden K P, Patil S B, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET /OFFSET study [J]. J Am Coll Cardiol, 2010, 56(3):185-193.[8] 段延章,刘素云. PCI治疗对AMI心室重构及NT-proBNP的影响[J]. 临床误诊误治,2013,26(8):90-92.[9] Brosh D, Assali A R, Mager A, et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality [J]. Am J Cardiol, 2007, 99(44): 442-445.[10] Wang X D, Zhang D F, Liu X B, et al.Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance [J]. Eur J Intern Med, 2012, 23(1):48-53.[11] Tantry U S, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding [J]. J Am Coll Cardiol, 2013, 62(24): 2261-2273.[12] Wang L, Wang X, Chen F. Clopidogrel resistance is associated with long-term thrombotic events in patients implanted with drug-eluting stents [J]. Drugs RD, 2010, 10(4): 219-224.[13] Bliden K P, DiChiara J, Tantry U S, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate [J]. J Am Coll Cardiol, 2007, 49(6): 657-666.[14] Neubauer H, Kaiser A F, Endres H G, et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance-the Bochum Clopidogrel and Aspirin Plan(bocla-plan) to improve antiplatelet therapy [J]. BMC Med, 2011, 9: 3.[15] Lombo B, Diez J G. Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes [J]. Core Evid, 2011, 6:31-642.[16] Gurbel P A, Bliden K P, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study [J]. Circulation, 2010, 121(10): 1188-1199.[17] Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin [J]. Eur Heart J, 2006, 27(9): 1038-1047.[18] Tantry U S, Bliden K P, Gurbel P A. AZD6140 [J]. Expert Opin Investig Drugs, 2007, 16(2): 225-229.[19] Scirica B M, Cannon C P, Emanuelsson H, et al. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO(Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy [J]. J Am Coll Cardiol, 2011, 57(19): 1908-1916. |
